Regeneron stock forecast
Regeneron’s weighted price is $1,098.59 in October 2027, with the bear case at 28%, the base case at 52% and the bull case at 20%. It hinges on whether Regeneron can replace weakening products with durable, profitable growth.
Where could Regeneron’s shares go?
The weighted price is $1,098.59 in October 2027, implying a 40% total return including dividends. It reaches $1,351.74 in October 2029, implying a 73% total return including dividends. The bear case carries 28% and the base case 52%. The bull case carries 20%.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 28 % | 742.63 (-5 %) | 645.48 (-17 %) | 553.66 (-28 %) |
| Base | 52 % | 1146.27 (+46 %) | 1300.10 (+66 %) | 1439.25 (+84 %) |
| Bull | 20 % | 1472.95 (+87 %) | 1814.43 (+131 %) | 2241.53 (+186 %) |
| Weighted | 100 % | 1098.59 (+40 %) | 1219.67 (+56 %) | 1351.74 (+73 %) |
What this means. The Weighted row is the probability-based average of the three cases, not a promise that the shares will reach that price.
What has to go right for Regeneron?
The base path assumes the ended $595 million Sanofi development deduction lifts retained economics, Dupixent continues to grow, manufacturing normalizes and EYLEA HD replaces part of legacy EYLEA. The bear case gives earnings of $5,400 million, then $5,000 million and $4,600 million as biosimilars, payer pressure and pipeline setbacks overwhelm that recovery. The bull case gives $7,000 million, then $8,000 million and $9,200 million, requiring durable Dupixent growth, successful launches and lower disruption costs. Dupixent sales reached $17,806.7 million in 2025, but combined U.S. EYLEA sales fell 12% in the latest quarter. Management’s R&D guidance is $6,500–$6,635 million, which limits near-term margin expansion. The analyst next-twelve-month EPS estimate is $62.5594, supporting recovery but not guaranteeing it.
How much cash does Regeneron really make?
Free cash flow subtracts investment in productive assets from operating cash. On the broader definition used here, $1,213.7 million of capital spending left $3,765.2 million of free cash flow. Regeneron’s own measure was $4,080.5 million because it excluded purchased intangible rights. Those rights included the $155.0 million voucher and $160.3 million of Libtayo contingent consideration.
Stock compensation requires a further owner-focused adjustment. Regeneron recorded $993.7 million of stock-based compensation in 2025. It does not immediately consume cash, but it transfers ownership to employees or requires repurchases to offset dilution. Deducting it produces analytical “real free cash flow” of $2,771.5 million, or 19.3% of revenue.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 4,978.9 | 4,420.5 | 4,594.0 | 5,014.9 | 7,081.3 |
| − Capital spending | 1,213.7 | 881.6 | 926.4 | 1,616.9 | 551.9 |
| = Free cash flow | 3,765.2 | 3,538.9 | 3,667.6 | 3,398.0 | 6,529.4 |
| − Stock pay | 993.7 | 982.8 | 885.0 | 725.0 | 601.7 |
| = Real free cash flow | 2,771.5 | 2,556.1 | 2,782.6 | 2,673.0 | 5,927.7 |
| Free cash flow, % of revenue | 26.3% | 24.9% | 28.0% | 27.9% | 40.6% |
| Real free cash flow, % of revenue | 19.3% | 18.0% | 21.2% | 22.0% | 36.9% |
What this means. The company's own free cash flow is higher because it leaves out payments for intangible assets, such as Libtayo rights, while our count treats them as spending.
What does an investor pay for Regeneron today?
At $788.48 and 19.5x trailing earnings, the price implies about $40.43 per share. A forward P/E of 12.6x implies about $62.58 per share. If the definitions match, investors are assuming roughly 55% earnings growth, even though the forward number has not yet been earned.
| Today (Oct 16, 2026) | |
|---|---|
| Share price | 788.48 |
| Market value (calculated) | 81,177.4 |
| Enterprise value (calculated) | 75,889.4 |
| P/E, last 12 months (calculated) | 19.5x |
| P/E, next 12 months (calculated) | 12.6x |
| Free cash flow yield (calculated) | 4.6% |
| Real free cash flow yield (calculated) | 3.4% |
What this means. Enterprise value is lower than market value because the company has more cash and short-term investments than debt, making the business effectively cheaper after using that cash.